Top

Published in:

01-05-2019 | Hepatocellular Carcinoma | Editorial Comment

RFA vs resection of HCC: exploring the past to improve the future

Author: Marcel C. Langenbach

Published in: European Radiology | Issue 5/2019

Excerpt

The decision for the treatment of hepatocellular carcinoma (HCC) is based on the Barcelona Cancer Liver Classification (BCLC) which has been established in 1999. The treatment options are still of intense research interest with regular modification of these guidelines. …

Forner A, Reig ME, de Lope CR, Bruix J (2010) Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 30:061–074. https://doi.org/10.1055/s-0030-1247133 CrossRef

Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases (2005) Management of hepatocellular carcinoma. Hepatology 42:1208–1236. https://doi.org/10.1002/hep.20933 CrossRef

Sommer CM, Stampfl U, Kauczor HU, Pereira PL (2014) National S3 guidelines on hepatocellular carcinoma. Radiologe 54:642–653. https://doi.org/10.1007/s00117-014-2656-0 CrossRefPubMed

Pompili M, Saviano A, de Matthaeis N et al (2013) Long-term effectiveness of resection and radiofrequency ablation for single hepatocellular carcinoma ≤3 cm. Results of a multicenter Italian survey. J Hepatol 59:89–97. https://doi.org/10.1016/j.jhep.2013.03.009 CrossRefPubMed

Yamagishi S, Midorikawa Y, Nakayama H et al (2018) Liver resection for recurrent hepatocellular carcinoma after radiofrequency ablation therapy. Hepatol Res. https://doi.org/10.1111/hepr.13293

de Stefano G, Farella N, Scognamiglio U et al (2015) Sorafenib after RFA in HCC patients: a pilot study. Hepatogastroenterology 62:261–263PubMed

Geschwind JF, Kudo M, Marrero JA et al (2016) TACE treatment in patients with Sorafenib-treated Unresectable hepatocellular carcinoma in clinical practice: final analysis of GIDEON. Radiology 279:630–640. https://doi.org/10.1148/radiol.2015150667 CrossRefPubMed

Longo V, Gnoni A, Casadei Gardini A et al (2017) Immunotherapeutic approaches for hepatocellular carcinoma. Oncotarget 8:33897–33910. https://doi.org/10.18632/oncotarget.15406 CrossRefPubMedPubMedCentral

Title: RFA vs resection of HCC: exploring the past to improve the future
Author: Marcel C. Langenbach
Publication date: 01-05-2019
Publisher: Springer Berlin Heidelberg
Keywords: Hepatocellular Carcinoma
Hepatocellular Carcinoma
Sorafenib
Published in: European Radiology / Issue 5/2019
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-019-6000-y

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

RFA vs resection of HCC: exploring the past to improve the future

Excerpt

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 5/2019

Double-inversion recovery with synthetic magnetic resonance: a pilot study for assessing synovitis of the knee joint compared to contrast-enhanced magnetic resonance imaging

Evaluation of renal dysfunction using texture analysis based on DWI, BOLD, and susceptibility-weighted imaging

Validation of overestimation ratio and TL-SVS as imaging biomarker of cardioembolic stroke and time from onset to MRI

Deep learning analysis of left ventricular myocardium in CT angiographic intermediate-degree coronary stenosis improves the diagnostic accuracy for identification of functionally significant stenosis

The evolution of image reconstruction for CT—from filtered back projection to artificial intelligence

Prediction of sorafenib treatment–related gene expression for hepatocellular carcinoma: preoperative MRI and histopathological correlation